Being with bevacuzimab and to a lesser extent imatinib, the only anti-VEGF therapies clinically approved and despite positive results in its ability to impair tumor growth and cancer progression62, the clinical impact of sunitinib is currently questioned as contradictory results have been obtained in the context of tumor metastasis. The gene discussed is VEGFA; the disease is cancer.